Atrial fibrillation is the most common sustained cardiac arrhythmia which is often troublesome to manage. Currently, rhythm and rate control medications are the mainstays of therapy. In 2 amiodarone-refractory highly symptomatic patients, an innovative approach using ranolazine, which selectively acts on Na+ channels and delays atrial depolarization, was tried successfully
Despite recent advances in our understanding of the mechanisms and consequences of atrial fibrillati...
Ranolazine is a relatively novel antiischemic/antianginal compound with antiarrhythmic properties. W...
Despite advances in drug therapy for the treatment of atrial fibrillation (AF), there continues to b...
AbstractAtrial fibrillation is the most common sustained cardiac arrhythmia which is often troubleso...
Background—The development of selective atrial antiarrhythmic agents is a current strategy for suppr...
Atrial fibrillation (AF) is a difficult arrhythmia to manage with antiarrhythmic agents. Amiodarone ...
Ranolazine has been shown to produce atrial-selective depres-sion of sodium channel-dependent parame...
Background Currently available antiarrhythmic agents for the treatment of atrial fibrillation (AF) h...
Background: Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High dose or...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
Atrial fibrillation is the most common disorder of cardiac rhythm. In spite of diagnosis simplicity,...
Introduction: Pharmacological rhythm control of atrial fibrillation (AF) in patients with structural...
The aim of this study was to investigate the effects of a combination of ranolazine with different s...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The la...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
Despite recent advances in our understanding of the mechanisms and consequences of atrial fibrillati...
Ranolazine is a relatively novel antiischemic/antianginal compound with antiarrhythmic properties. W...
Despite advances in drug therapy for the treatment of atrial fibrillation (AF), there continues to b...
AbstractAtrial fibrillation is the most common sustained cardiac arrhythmia which is often troubleso...
Background—The development of selective atrial antiarrhythmic agents is a current strategy for suppr...
Atrial fibrillation (AF) is a difficult arrhythmia to manage with antiarrhythmic agents. Amiodarone ...
Ranolazine has been shown to produce atrial-selective depres-sion of sodium channel-dependent parame...
Background Currently available antiarrhythmic agents for the treatment of atrial fibrillation (AF) h...
Background: Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High dose or...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
Atrial fibrillation is the most common disorder of cardiac rhythm. In spite of diagnosis simplicity,...
Introduction: Pharmacological rhythm control of atrial fibrillation (AF) in patients with structural...
The aim of this study was to investigate the effects of a combination of ranolazine with different s...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The la...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
Despite recent advances in our understanding of the mechanisms and consequences of atrial fibrillati...
Ranolazine is a relatively novel antiischemic/antianginal compound with antiarrhythmic properties. W...
Despite advances in drug therapy for the treatment of atrial fibrillation (AF), there continues to b...
DOI
Add to ORKG